1 / 38

FIBRINOLSIS SYSTEM

FIBRINOLSIS SYSTEM. Ahmad Shihada Silmi Msc, FIBMS IUG Faculty of Sciences Medical Technology Dep. History. In 1937 MaCfarlane reported that damage tissues release a substance (activator that activates the inert precursor called Plasminogen ). Fibrinolysis.

zacherya
Download Presentation

FIBRINOLSIS SYSTEM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FIBRINOLSIS SYSTEM Ahmad Shihada Silmi Msc, FIBMS IUG Faculty of Sciences Medical Technology Dep.

  2. History • In 1937 MaCfarlane reported that damage tissues release a substance (activator that activates the inert precursor called Plasminogen).

  3. Fibrinolysis • Process of removing fibrin from the vasculature • Key Players • Plasminogen • Plasminogen activators (PA) • Active enzyme plasmin (PLN) • Fibrin • Fibrin/Fibrinogen degradation products • Inhibitors of Plasminogen activators and PLN

  4. Function of Fibrinolysis in Homeostasis • Fibrinolysisis the system whereby the temporary fibrin clot is systematically and gradually dissolved as the vessel heals in order to restore normal blood flow. • Is the body’s defense against occlusion of blood vessels

  5. Fibrinolytic System, cont. • Sensitive to imbalances • Restricts fibrin formation to area of injury • Initiated when coagulation cascade begins • Dissolves clot by digestion of fibrin

  6. Overview • Under the influence of thrombin. • Fibrinogen cleaved into fibrin monomers • Fibrin monomers are cleaved into fibrin degradation products or fibrin split products

  7. Process summary • Once clotting begins, the fibrinolytic system comes to life • Plasminogen (PLG) binds to fibrin in the developing thrombus • Tissue-type PLG activator (tPA) also binds to fibrin, increasing its enzymatic activity to convert plasminogen to plasmin (PLN) • Complex formation of tPA, PLG and fibrin results in the break-down of fibrin • PLN then further digest fibrin to soluble degradation products making fibrin fragments

  8. Plasminogen • Plasminogen is a single-chain glycoprotein with a Mwt of 90,000 d • Produced in the liver • Found in normal plasma • Plasminogen is the inactive precursor (zymogene) of the trypsin-like serine protease plasmin.

  9. Plasminogen • Following injury, binds to fibrin during clot formation along with plasminogen activators • Plasminogen: once needed converts to its active form called, Plasmin. • Increased concentrations are found in association with inflammation.

  10. When Plasminogen is activated, it unfolds to expose its potent enzymatic domains.

  11. Activators of Fibrinolysis • Contact Phase/Intrinsic • Occurs by interactions of the contact factors (XIIa, HMWK, and PK) following intrinsic pathway activation(collagen exposure) • Physiologic (secretions) • Activators released from tissues extrinsic to the blood • tPA: tissue- type PLG activator • Found in endothelial cells of small vessels • uPA: urokinase-type PLG activator • Made in renal tubular epithelium and vascular epithelium • Found in urine and plasma • Exogenous activation • Via medications given to lyse pathogenic clots (i.e. pulmonary emboli) • Example includes Streptokinase

  12. Activators

  13. Another classification seen: Activation of Plasminogencan occurs due to • • Intrinsic Plasminogen Activation • • Extrinsic Plasminogen Activation • • Exogenous Plasminogen Activation • • Plasminogen Activation in Secretory Ducts. (Fig)

  14. FIBRINOLSIS SYSTEM

  15. FIBRINOLSIS SYSTEM • For therapeutic destruction of thrombosis, Urokinase, a trypsin-like protease, may be administered to a patient to activate plasminogen to plasmin and induce Fibrinolysis. • Streptokinase is another agent used to activate Plasminogen to plasmin • Tissue Plasminogen activator (tPA) is an agent used for the treatment of thrombosis. It released in vivo on endothelial cell damage and can be manufactured in vitro through recombinant DNA techniques.

  16. FIBRINOLYTIC SYSTEM

  17. FIBRINOLSIS SYSTEM • FIG. Simple overview of Fibrinolytic pathway. • Tissue plasminogen activatorsactivateplasminogen within clot to plasmin, which slowly dissolves fibrin clot. • Inhibitors are neutralized by protein C—S complex, thus enhancing fibrinolysis.

  18. FIBRINOLSIS SYSTEM • Tissue Plasminogen Activators, which convert Plasminogen to Plasmin are released from injured vessel walls. • Plasmin is trapped within the clot, and clot lysis begin slowly as soon as the clot is formed, with fibrin degradation products being released in the plasma. • Lysis is slow because of fibrin clot stabilization by factor XIII. • Protein S and C are two substance that enhance fibrinolysis and inactivateTissue Plasminogen Activators (tPA inhibitor).

  19. Plasmin • Normally is not present in the blood in an active form. • A non-specific Proteolytic enzyme • Dissolves fibrin/fibrinogen clots into protein fragments that are cleared from plasma by the liver • Provides a positive feedback loop for forming more Plasminogen

  20. Plasmin • Can digest or destroy fibrinogen, fibrin and factors V & VIII. • Promotes Coagulation and activates the Kinine and Complement systems. • Highly regulated • Temporarily active • Local

  21. FIBRINOLSIS SYSTEM Physiologic Fibrinolysis Many similarities exist between Coagulation and Fibrinolytic systems. • AS there are checks and balances in the formation of clot • There are similar mechanism for dissolution of the clot to promote wound Healing. • Important that bleeding does not recur because of premature lysing of the clot.

  22. FIBRINOLSIS SYSTEM

  23. FIBRINOLSIS SYSTEM • Summary • Fibrinolysis is dependent on the enzyme PLASMIN • Tissue Plasminogen Activators, which convert Plasminogen to Plasmin are released from injured vessel walls. • Plasminogen (A zymogen) which normally present in plasma is converted to Plasmin by the action of specific enzyme called Plasminogen Activators. • Activation of Plasminogencan occurs due to • Intrinsic, Extrinsic, Exogenous Plasminogen Activation, andActivation in Secretory Ducts.

  24. FIBRINOLSIS SYSTEM • Plasminogen is a part of any clot because of the tendency of fibrin to absorb plasminogen from the plasma in normal circumstances. • When plasminogen activators performed their function, plasmin is formed within the clot, which gradually dissolves the clot while leaving time for tissue repair. • Free Plasmin is released to the plasma, however, anti-plasmin is there immediately destroy any plasmin released from the clot.

  25. FIBRINOLSIS SYSTEM • When Pathologic Coagulation processes are involved, excessive free plasmin is released to the plasma • In these situation, the available anti-plasmin is depleted and plasmin begins destroying components other than fibrin, including, fibrinogen, factor V and VIII and other factors.

  26. FIBRINOLSIS SYSTEM FIBRIN(OGEN) DEGRADATION by PLASMIN • In the process of fibrinogen or fibrin degradation by plasmin within a clot, specific molecular fragments are produced called Fibrin (ogen) Degradation Products (FDP) or Fibrin (ogen) Split Products (FSP) • These degradation products are removed by the reticuloendothelial system and other organs. • The sequence of reaction in the degradation of Fibrin(ogen) by plasmin are X, Y, D (D-D dimer) and E.

  27. Fibrinogen Structure Graphic accessed at URL http://coursewareobjects.elsevier.com/objects/elr/Rodak3e/IC/jpg/Chapter40/040006.jpg, 2008.

  28. 1 - Damaged endothelia secrete TPA. 2 – TPA activates plasminogen bound to fibrin clot. 3 - Free TPA circulates bound to PAI-1 and is cleared from plasma. Plasmin systematically hydrolyzes lysine & arginine peptide bonds of the fibrin polymer. ‘P’ indicates sites where plasmin cleaves the fibrin polymer. Fibrinolytic Mechanisms Graphic accessed at URL http://www.nature.com/bmt/journal/v41/n8/images/1705990f1.jpg, 2008. Graphic accessed at URL http://coursewareobjects.elsevier.com/objects/elr/Rodak3e/IC/jpg/Chapter40/040006.jpg, 2008.

  29. Plasmin Degradation of Fibrinogen E Fibrinogen D D plasmin E D D Fragment X: small peptides from carboxyl end of α chain removed plasmin E Fragment Y + Fragment D D D plasmin E D Fragment D + Fragment E

  30. Plasminogen Intrinsic/contact activation Physiologic activation Exogenous activation Plasmin Fibrin clot Fibrinogen Fibrin Degradation Fibrinogen Products Degradation Products X,Y,D=D,E X,Y,D,E,D

  31. FIBRINOLSIS SYSTEM • Fibrin(ogen) Degradation by Plasmin • Fragment X and Y are referred to as early degradation products • Fragment D and E are late degradation products • Fragment X is the first and the largest fragment formed (Mwt 250,000 d) • Fragment X is the results of Plasmin (P) cleavage of the terminal portion of the alpha (α) chains from a fibrin polymer • Fragment X is cleaved by Plasmin (P) to form two fragments called Y (YY) and an intermediate complex (DXD)

  32. FIBRINOLSIS SYSTEM • This complex is further cleaved into intermediate complexes DED and DY/DY until finally, fragment E and D (D-D dimer) are formed. • A single fragment D has Mwt 90,000 d and that the D-D dimer is 180,000 d • Presence of D-D dimer is a specific indication of in vivo fibrinolysis, namely, intravascular thrombin formation leading to fibrin formation and its subsequent degradation

  33. What is D-dimer • D-dimer is a protein that represents an area of fibrin which contain cross-linked regions used as clot stabilizers. • D-dimer present in circulation is used as an indicator of a blood clot being formed and broken down somewhere in the body

  34. Pathologic Effect of FDPs • The FDPs are significant because of their haemostatic effects, which include; • Anti-thrombin activity • Interference with polymerization of fibrin monomer • Interference with platelet activity

  35. The early and large fragments (X and Y) along with the intermediate FDPs, are important in exerting anticoagulant Effect • Fragment Y and D inhibit fibrin polymerization • Fragment E is a powerful inhibitor of thrombin • All four fragments, but particularly low molecular weight FDP, have an affinity coating platelet membrane and therefore, cause a clinically significant platelet dysfunction by inhibiting aggregation.

  36. Fibrinolytic Inhibitors • 1- Alpha-2- Anti-plasmin (α2 anti-plasmin) • An (α2) glyco-protein • Most important naturally occurring inhibitor • The principle inhibitors of fibrinolysis by binding with plasmin that is free in the plasma (neutralizing plasmin) • Inhibits the clot-promoting activities of plasma kallikrein • Inhibits the serine proteases Xlla, XIa, IIa and Xa • Hereditary deficiencies have been associated with, Excessive clotting (DIC) Excessive fibrinolysis

  37. 2- Alpha 2 Macroglobulin • Large naturally occurring plasma GP • Inhibits component in both the fibrinolysis and coagulation systems • Inhibits plasmin after alpha 2 anti-plasmin depletion 3- Alpha 1 Antitrypsin • The third most important naturally occurring inhibitor of fibrinolytic system. Inactivates plasmin slowly and does not bind plasmin until both alpha2 anti-plasmin and alpha 2 macroglobulin are saturated • Inhibits coagulation by its potent inhibitory effects on factor XIa

  38. Other Inhibitors • Anti-thrombin III, inhibits fibrinolysis by inhibiting plasmin and kallikrein • The C1 inactivator also inhibits plasmin.

More Related